Eli Lilly to Launch Alzheimer's Disease Therapy Lormalzi in India This Month

Eli Lilly and Company Set to Launch Lormalzi Injection for Alzheimer's Disease in India

Eli Lilly and Company, a leading global pharmaceutical major, will introduce its Lormalzi injection in India this month for the treatment of Alzheimer's disease with mild cognitive impairment or those in the mild dementia stage of the disease. According to a senior company official, the injectable therapy is being brought to India at a critical time when the number of people living with dementia is expected to double by 2036 to over 19 million.

Lormalzi (donanemab, 350 mg/20 ml IV vial) is the first and only once-monthly amyloid plaque-targeting therapy. Amyloid is a protein produced naturally in the body that can clump together to create amyloid plaques, leading to memory and thinking issues associated with Alzheimer's disease. The excessive buildup of amyloid plaques in the brain can be removed by the prescription-only drug Lormalzi, helping to slow the decline in cognitive ability.

The Pricing of Lormalzi

Read also: Pfizer Introduces Novel Myeloma Treatment in India for Patients with Limited Therapeutic Options

The pricing of Lormalzi has been set at Rs 91,688 per month for a 350 milligram vial. However, to ensure broader access for eligible patients, the company will be implementing an alternative access program. This program aims to provide patients with more affordable options for the treatment.

Key Features of Lormalzi

Lormalzi is a disease-modifying monthly product that targets the amyloid plaque in the brain. It is given for 18 months, making it a finite period of treatment. In contrast to other products available in the marketplace, Lormalzi addresses the root cause of the disease by removing the amyloid plaques, rather than just treating the symptoms.

Market Rollout and Potential in India

Read also: Lilly Launches Novel Alzheimer's Treatment Lormalzi in India at Rs 91,688 per Vial

The market rollout of Lormalzi is expected to take place this month, with the product becoming available for patients within the next couple of weeks. The company sees significant potential for the product in India, where there are currently 8.8 million people living with dementia. This number is expected to double by 2036, making Lormalzi a crucial treatment option for patients suffering from Alzheimer's disease.

Marketing Authorization and Strategy

Eli Lilly and Company has received marketing authorisation for Lormalzi from the Central Drugs Standard Control Organization (CDSCO) for the treatment of Alzheimer's disease with mild cognitive impairment or those in the mild dementia stage of disease. The company views Lormalzi as a key part of its strategy to bring innovation to India, making a meaningful difference for diseases that are impacting people living in India today.

Note: The table above provides a comparison of the company and product mentioned in the article.